Cargando…
Identification and Roles of miR-29b-1-3p and miR29a-3p-Regulated and Non-Regulated lncRNAs in Endocrine-Sensitive and Resistant Breast Cancer Cells
SIMPLE SUMMARY: Estrogen receptor α (ERα) is a key driver and clinical target in breast cancer, with ~75% of women having ERα+ breast tumors at diagnosis. Endocrine therapies (tamoxifen and aromatase inhibitors) targeting ERα are the preferred treatment for ER+/HER2− breast tumors due to their effic...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8307416/ https://www.ncbi.nlm.nih.gov/pubmed/34298743 http://dx.doi.org/10.3390/cancers13143530 |
_version_ | 1783728041296396288 |
---|---|
author | Muluhngwi, Penn Klinge, Carolyn M. |
author_facet | Muluhngwi, Penn Klinge, Carolyn M. |
author_sort | Muluhngwi, Penn |
collection | PubMed |
description | SIMPLE SUMMARY: Estrogen receptor α (ERα) is a key driver and clinical target in breast cancer, with ~75% of women having ERα+ breast tumors at diagnosis. Endocrine therapies (tamoxifen and aromatase inhibitors) targeting ERα are the preferred treatment for ER+/HER2− breast tumors due to their efficacy and tolerance in most patients. However, patients develop resistance to these endocrine therapies and disease progression to metastasis remains a major clinical problem. There are multiple mechanisms involved in the progression to endocrine resistance, including epigenetic changes in non-coding RNAs that regulate cellular pathways leading to cancer progression and metastasis. This paper summarizes the role of long non-coding RNAs regulated by miR-29 in endocrine-resistant breast cancer. ABSTRACT: Despite improvements in the treatment of endocrine-resistant metastatic disease using combination therapies in patients with estrogen receptor α (ERα) primary tumors, the mechanisms underlying endocrine resistance remain to be elucidated. Non-coding RNAs (ncRNAs), including microRNAs (miRNA) and long non-coding RNAs (lncRNA), are targets and regulators of cell signaling pathways and their exosomal transport may contribute to metastasis. Previous studies have shown that a low expression of miR-29a-3p and miR-29b-3p is associated with lower overall breast cancer survival before 150 mos. Transient, modest overexpression of miR-29b1-3p or miR-29a-3p inhibited MCF-7 tamoxifen-sensitive and LCC9 tamoxifen-resistant cell proliferation. Here, we identify miR-29b-1/a-regulated and non-regulated differentially expressed lncRNAs in MCF-7 and LCC9 cells using next-generation RNA seq. More lncRNAs were miR-29b-1/a-regulated in LCC9 cells than in MCF-7 cells, including DANCR, GAS5, DSCAM-AS1, SNHG5, and CRND. We examined the roles of miR-29-regulated and differentially expressed lncRNAs in endocrine-resistant breast cancer, including putative and proven targets and expression patterns in survival analysis using the KM Plotter and TCGA databases. This study provides new insights into lncRNAs in endocrine-resistant breast cancer. |
format | Online Article Text |
id | pubmed-8307416 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-83074162021-07-25 Identification and Roles of miR-29b-1-3p and miR29a-3p-Regulated and Non-Regulated lncRNAs in Endocrine-Sensitive and Resistant Breast Cancer Cells Muluhngwi, Penn Klinge, Carolyn M. Cancers (Basel) Article SIMPLE SUMMARY: Estrogen receptor α (ERα) is a key driver and clinical target in breast cancer, with ~75% of women having ERα+ breast tumors at diagnosis. Endocrine therapies (tamoxifen and aromatase inhibitors) targeting ERα are the preferred treatment for ER+/HER2− breast tumors due to their efficacy and tolerance in most patients. However, patients develop resistance to these endocrine therapies and disease progression to metastasis remains a major clinical problem. There are multiple mechanisms involved in the progression to endocrine resistance, including epigenetic changes in non-coding RNAs that regulate cellular pathways leading to cancer progression and metastasis. This paper summarizes the role of long non-coding RNAs regulated by miR-29 in endocrine-resistant breast cancer. ABSTRACT: Despite improvements in the treatment of endocrine-resistant metastatic disease using combination therapies in patients with estrogen receptor α (ERα) primary tumors, the mechanisms underlying endocrine resistance remain to be elucidated. Non-coding RNAs (ncRNAs), including microRNAs (miRNA) and long non-coding RNAs (lncRNA), are targets and regulators of cell signaling pathways and their exosomal transport may contribute to metastasis. Previous studies have shown that a low expression of miR-29a-3p and miR-29b-3p is associated with lower overall breast cancer survival before 150 mos. Transient, modest overexpression of miR-29b1-3p or miR-29a-3p inhibited MCF-7 tamoxifen-sensitive and LCC9 tamoxifen-resistant cell proliferation. Here, we identify miR-29b-1/a-regulated and non-regulated differentially expressed lncRNAs in MCF-7 and LCC9 cells using next-generation RNA seq. More lncRNAs were miR-29b-1/a-regulated in LCC9 cells than in MCF-7 cells, including DANCR, GAS5, DSCAM-AS1, SNHG5, and CRND. We examined the roles of miR-29-regulated and differentially expressed lncRNAs in endocrine-resistant breast cancer, including putative and proven targets and expression patterns in survival analysis using the KM Plotter and TCGA databases. This study provides new insights into lncRNAs in endocrine-resistant breast cancer. MDPI 2021-07-14 /pmc/articles/PMC8307416/ /pubmed/34298743 http://dx.doi.org/10.3390/cancers13143530 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Muluhngwi, Penn Klinge, Carolyn M. Identification and Roles of miR-29b-1-3p and miR29a-3p-Regulated and Non-Regulated lncRNAs in Endocrine-Sensitive and Resistant Breast Cancer Cells |
title | Identification and Roles of miR-29b-1-3p and miR29a-3p-Regulated and Non-Regulated lncRNAs in Endocrine-Sensitive and Resistant Breast Cancer Cells |
title_full | Identification and Roles of miR-29b-1-3p and miR29a-3p-Regulated and Non-Regulated lncRNAs in Endocrine-Sensitive and Resistant Breast Cancer Cells |
title_fullStr | Identification and Roles of miR-29b-1-3p and miR29a-3p-Regulated and Non-Regulated lncRNAs in Endocrine-Sensitive and Resistant Breast Cancer Cells |
title_full_unstemmed | Identification and Roles of miR-29b-1-3p and miR29a-3p-Regulated and Non-Regulated lncRNAs in Endocrine-Sensitive and Resistant Breast Cancer Cells |
title_short | Identification and Roles of miR-29b-1-3p and miR29a-3p-Regulated and Non-Regulated lncRNAs in Endocrine-Sensitive and Resistant Breast Cancer Cells |
title_sort | identification and roles of mir-29b-1-3p and mir29a-3p-regulated and non-regulated lncrnas in endocrine-sensitive and resistant breast cancer cells |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8307416/ https://www.ncbi.nlm.nih.gov/pubmed/34298743 http://dx.doi.org/10.3390/cancers13143530 |
work_keys_str_mv | AT muluhngwipenn identificationandrolesofmir29b13pandmir29a3pregulatedandnonregulatedlncrnasinendocrinesensitiveandresistantbreastcancercells AT klingecarolynm identificationandrolesofmir29b13pandmir29a3pregulatedandnonregulatedlncrnasinendocrinesensitiveandresistantbreastcancercells |